Everolimus Reduces ⁸⁹Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors

Abstract

This study demonstrates variable (89)Zr-bevacizumab PET tumor uptake in NET patients. (89)Zr-bevacizumab tumor uptake diminished during everolimus treatment. Serial (89)Zr-bevacizumab PET might be useful as an early predictive biomarker of anti-VEGF-directed treatment in NET patients.